NEWS

| MEMO Therapeutics

Basel, Switzerland, Feb 1st, 2019 - This is a major step in the technology development at Memo since we are now able to directly screen antibody repertoire libraries from rare patients or immunized animals for antibodies with the desired functional activity in a single day.

| MEMO Therapeutics

Basle, Switzerland, June 11, 2018 - Memo Therapeutics AG announces that Dr. Karsten Fischer was appointed as Chief Executive Officer of the company effective June 01, 2018.

| MEMO Therapeutics

Basel, Switzerland, May 9th 2018 – MEMO Therapeutics AG (“MEMO”), an innovator in the field of antibody discovery and human immune repertoire analysis, announced today the closing of a Series A2 financing round of CHF 5.0 million.

| MEMO Therapeutics

Memo Therapeutics made it to the top 100 of Swiss startups for the third time in a row and is within the top 5 biotech companies. See entire list of companies.

| MEMO Therapeutics

Memo Therapeutics AG was awarded a new CTI grant

| MEMO Therapeutics

Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform

| MEMO Therapeutics

memo at conferences

| MEMO Therapeutics

Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.

| MEMO Therapeutics

MEMO’s poster introducing the MemoMAB™ technology platform for the banking and screening of human...

| MEMO Therapeutics

MEMO’s abstract has been accepted for Poster Discussion presentation...

| MEMO Therapeutics

Memo Therapeutics made it to the top 100 of Swiss startups for the second time in a row and is within the top 10 biotech companies.